Burning Rock Dx recently achieved full scores in four External Quality Assessment (EQA) programs organized by three leading authorities: the National Center for Clinical Laboratories of China (NCCL), the College of American Pathologists (CAP), and the European Molecular Genetics Quality Network (EMQN).

To date，Burning Rock & CTONG Lab has successfully passed 323 EQA programs conducted by internationally recognized organizations, including NCCL, PQCC, EMQN, and CAP—demonstrating long-term excellence in quality management and testing performance.

Comprehensive Validation Across Multiple Tumor Types

The four EQA programs covered hereditary breast and ovarian cancer, breast cancer, and other solid tumors, involving diverse genes and variant types. Using Burning Rock Dx’s products such as OncoScreen Plus and BRCA1/BRCA2 Assay, the laboratory accurately identified all variants in 15 samples, fully validating analytical accuracy and standardization across different technologies and sample types.

Rigorous Quality System Backed by Global Certifications

With over a decade of deep expertise in oncology NGS, Burning Rock Dx adheres to the principle of “Precision Medicine with Quality First”, establishing a comprehensive quality assurance system across the entire testing workflow. The company has successfully passed technical reviews for high-throughput sequencing laboratory by the Guangdong Clinical Laboratory Center and holds multiple international certifications, including CAP, CLIA, ISO 15189, ISO 9001, and GMP, ensuring reliable, accurate, and compliant test results.

Driving High-Quality Development in Precision Oncology

Looking ahead, Burning Rock Dx will continue to uphold the highest laboratory operation standards, advance technological innovation, and continuously optimize its quality management system. By delivering high-quality precision oncology solutions to clinical researchers, pharmaceutical innovators, and patients worldwide, the company remains committed to advancing global precision medicine.

EQA Program Details

☑️ NCCL EQA：In the 2025 EQA for Somatic Mutation Detection in Solid Tumors by NGS organized by NCCL, the laboratory analyzed six DNA samples using OncoScreen Plus. Clinically actionable variants—including SNVs and short indels (LOD ≤5%)—were accurately detected, fully meeting EQA requirements and achieving a full-score result.

☑️ CAP EQA：In the CAP BRCA-B 2025 BRCA1/2 Sequencing Proficiency Test, three BRCA1/2 DNA samples from female patients with breast and ovarian cancer were analyzed using BRCA1/BRCA2 Assay. Accurate detection and interpretation led to a full-score performance, highlighting compliance and reliability in hereditary cancer testing.

☑️ EMQN EQA：In the EMQN ONCOGENE PANEL | 2025 and BREAST CANCER (AKT pathway) [Tissue] | 2025 EQA programs, Burning Rock & CTONG Lab successfully detected key driver genes—including EGFR, BRAF, KRAS, NRAS, KIT, PIK3CA, AKT1, PTEN, ERBB2, and IDH2—from six FFPE samples using OncoScreen Plus. Submitted English reports met international standards in genotyping accuracy, interpretation, and documentation, earning full marks in both assessments.